• Belinostat (PXD101): Pan-HDAC Inhibitor for Epigenetic Ca...

  2026-03-14

  Belinostat (PXD101), a potent hydroxamate-type histone deacetylase inhibitor, demonstrates nanomolar pan-HDAC inhibition and robust suppression of tumor cell proliferation. Its validated activity in urothelial and prostate carcinoma models, along with precise mechanistic action, makes it a benchmark tool for epigenetic cancer therapy research.

• Belinostat (PXD101): Optimizing Pan-HDAC Inhibition in Ca...

  2026-03-13

  Belinostat (PXD101) stands out as a robust hydroxamate-type pan-HDAC inhibitor, enabling precise epigenetic modulation and effective suppression of tumor cell proliferation. This guide delivers actionable workflows, advanced troubleshooting, and comparative insights to help researchers unlock the full potential of Belinostat in urothelial and prostate cancer studies.

• Optimizing Cancer Epigenetics Research with GSK126 (EZH2 ...

  2026-03-13

  This article delivers an evidence-based, scenario-driven guide for leveraging GSK126 (EZH2 inhibitor) (SKU A3446) in cell viability and epigenetic assays, with actionable insights into experimental design, protocol optimization, data interpretation, and reliable sourcing. By integrating real-world laboratory challenges and recent literature, it empowers researchers to achieve reproducible, high-sensitivity results in oncology and epigenetics.

• Vorinostat: HDAC Inhibitor Workflows for Cancer Biology R...

  2026-03-12

  Vorinostat (SAHA) stands out as a gold-standard histone deacetylase inhibitor for cancer research, enabling precise epigenetic modulation and robust apoptosis assays. With its nanomolar potency, reproducible dose-response, and versatility across cell and animal models, Vorinostat empowers oncology labs to dissect chromatin remodeling and intrinsic apoptotic pathways with confidence.

• Belinostat (PXD101): Reproducible Pan-HDAC Inhibition for...

  2026-03-12

  This article delivers evidence-based strategies for overcoming common laboratory challenges in cell viability, proliferation, and cytotoxicity assays using Belinostat (PXD101), SKU A4096. Drawing on real-world scenarios, quantitative data, and vendor selection insights, we demonstrate how Belinostat (PXD101) from APExBIO supports robust and reproducible results in epigenetic cancer research.

• Minocycline HCl: Expanding Horizons in Inflammation and N...

  2026-03-11

  Explore how minocycline HCl, a semisynthetic tetracycline antibiotic, uniquely advances inflammation-related pathology research and neurodegenerative disease modeling. This article delivers a deeper, systems-level perspective on its mechanistic roles and integration with scalable regenerative platforms.

• AZ505: Potent and Selective SMYD2 Inhibitor for Epigeneti...

  2026-03-11

  AZ505, a potent and selective SMYD2 inhibitor from APExBIO, empowers researchers to interrogate the histone methylation pathway with unprecedented precision. Its substrate-competitive mechanism and robust selectivity profile make it indispensable for cancer biology, epigenetic regulation, and emerging models of fibrosis and inflammation.

• Toremifene Citrate: SERM Pharmacokinetics and Metabolism ...

  2026-03-10

  Explore the unique pharmacokinetics, metabolism, and advanced research applications of Toremifene Citrate, a leading oral selective estrogen receptor modulator for cancer research. This in-depth article provides fresh perspectives on SERM mechanisms and translational models, going beyond protocol guides to empower innovative breast cancer and endocrinology studies.

• Trichostatin A (TSA): Advanced Insights into HDAC Inhibit...

  2026-03-10

  Explore the multifaceted role of Trichostatin A as a potent histone deacetylase inhibitor for epigenetic research and cancer therapy. This article delivers a deeper analysis of TSA’s mechanistic action, translational applications, and its unique position in advancing oncology research.

• AZ505: Potent and Selective SMYD2 Inhibitor for Epigeneti...

  2026-03-09

  AZ505, a potent and selective SMYD2 inhibitor, enables precise investigation of protein lysine methyltransferase inhibition in epigenetic regulation and cancer biology research. Its substrate-competitive mechanism and high selectivity make it a robust benchmark tool for studying histone methylation pathways, with verified efficacy in disease models including gastric cancer, ESCC, and renal fibrosis.

• Minocycline HCl: Protocol Innovations for Neurodegenerati...

  2026-03-09

  Minocycline HCl is revolutionizing neurodegenerative and inflammation-related pathology research by bridging broad-spectrum antimicrobial action with advanced anti-inflammatory and neuroprotective workflows. This article provides stepwise protocols, troubleshooting solutions, and comparative insights for leveraging minocycline hydrochloride in scalable stem cell and extracellular vesicle (EV) models.

• Best Practices with DOT1L inhibitor EPZ-5676 (SKU A4166):...

  2026-03-08

  This article offers practical, scenario-driven guidance for using DOT1L inhibitor EPZ-5676 (SKU A4166) in cell proliferation and cytotoxicity assays, with a focus on reproducibility and assay optimization. Drawing from benchmark literature and real-world troubleshooting, we illustrate how EPZ-5676 outperforms alternatives in MLL-rearranged leukemia and epigenetic research. Researchers gain actionable protocols, data interpretation tips, and vendor selection insights to maximize assay reliability.

• SP2509: LSD1 Inhibitor for Acute Myeloid Leukemia Research

  2026-03-07

  SP2509 is a highly selective LSD1 antagonist that enables precise modulation of cancer epigenetics in acute myeloid leukemia (AML) models. Its potent, nanomolar inhibition and workflow-friendly properties support robust apoptosis induction and differentiation studies for translational research.

• Decitabine: DNA Methyltransferase Inhibitor for Cancer Ep...

  2026-03-06

  Decitabine (5-Aza-2'-deoxycytidine) from APExBIO stands at the forefront of cancer epigenetics, enabling precise DNA hypomethylation and robust tumor suppressor gene reactivation in both hematopoietic malignancy and solid tumor models. This guide delivers actionable workflows, troubleshooting strategies, and advanced applications to maximize research impact and reproducibility.

• Trichostatin A: HDAC Inhibitor Workflows for Cutting-Edge...

  2026-03-06

  Trichostatin A (TSA) from APExBIO stands as the gold-standard HDAC inhibitor for researchers driving breakthroughs in cancer biology and epigenetic regulation. This article delivers actionable experimental workflows, advanced troubleshooting, and comparative analysis, enabling scientists to maximize the reproducibility and impact of TSA in translational research.

16574 records 1/1105 page Next 12345 下5页 Last page